Kimberly K. Leslie

7.4k total citations · 1 hit paper
186 papers, 5.6k citations indexed

About

Kimberly K. Leslie is a scholar working on Molecular Biology, Obstetrics and Gynecology and Oncology. According to data from OpenAlex, Kimberly K. Leslie has authored 186 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Molecular Biology, 71 papers in Obstetrics and Gynecology and 53 papers in Oncology. Recurrent topics in Kimberly K. Leslie's work include Endometrial and Cervical Cancer Treatments (52 papers), Estrogen and related hormone effects (39 papers) and Ovarian cancer diagnosis and treatment (35 papers). Kimberly K. Leslie is often cited by papers focused on Endometrial and Cervical Cancer Treatments (52 papers), Estrogen and related hormone effects (39 papers) and Ovarian cancer diagnosis and treatment (35 papers). Kimberly K. Leslie collaborates with scholars based in United States, Canada and China. Kimberly K. Leslie's co-authors include Kristina W. Thiel, Shujie Yang, Donghai Dai, Eric J. Devor, Xiangbing Meng, David Feeny, Robert B. Bourne, Peter Tugwell, Meenakshi Singh and Andreas Laupacis and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Kimberly K. Leslie

182 papers receiving 5.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The effect of elective total hip replacement on health-related quality of life.

1993 511 citations Kimberly K. Leslie et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kimberly K. Leslie United States	42	1.9k	1.7k	1.3k	1.3k	1.2k	186	5.6k
Adnan Munkarah United States	41	1.9k 1.0×	1.8k 1.1×	2.0k 1.5×	1.5k 1.2×	450 0.4×	182	6.2k
Lukas Hefler Austria	42	1.2k 0.6×	1.3k 0.8×	1.3k 1.0×	1.5k 1.2×	468 0.4×	208	5.1k
Robert Morris United States	42	2.2k 1.1×	1.2k 0.7×	1.3k 1.0×	1.2k 0.9×	402 0.3×	195	6.0k
Olaf Ortmann Germany	41	1.6k 0.8×	619 0.4×	2.2k 1.7×	1.7k 1.4×	1.6k 1.4×	346	6.3k
Sven� Mahner Germany	41	1.5k 0.8×	1.7k 1.0×	2.3k 1.8×	1.6k 1.3×	366 0.3×	337	6.2k
Achim Rody Germany	34	1.5k 0.8×	654 0.4×	699 0.5×	1.6k 1.3×	381 0.3×	238	4.6k
John J. Kavanagh United States	39	1.5k 0.8×	745 0.4×	1.3k 1.0×	1.4k 1.1×	336 0.3×	121	4.7k
Alain G. Zeimet Austria	43	2.2k 1.1×	479 0.3×	1.3k 1.0×	2.1k 1.6×	409 0.3×	173	5.1k
Satoru Nagase Japan	36	1.6k 0.8×	1.4k 0.8×	1.1k 0.9×	717 0.6×	219 0.2×	174	4.3k
David Cibula Czechia	46	1.2k 0.6×	3.4k 2.0×	4.1k 3.2×	2.1k 1.7×	543 0.5×	372	8.0k

Countries citing papers authored by Kimberly K. Leslie

Since Specialization

Citations

This map shows the geographic impact of Kimberly K. Leslie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kimberly K. Leslie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kimberly K. Leslie more than expected).

Fields of papers citing papers by Kimberly K. Leslie

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kimberly K. Leslie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kimberly K. Leslie. The network helps show where Kimberly K. Leslie may publish in the future.

Co-authorship network of co-authors of Kimberly K. Leslie

This figure shows the co-authorship network connecting the top 25 collaborators of Kimberly K. Leslie. A scholar is included among the top collaborators of Kimberly K. Leslie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kimberly K. Leslie. Kimberly K. Leslie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Steinkamp, Mara P., Irina V. Lagutina, Yan Guo, et al.. (2025). Novel p53 reactivators that are synergistic with olaparib for the treatment of gynecologic cancers with mutant p53. Translational Oncology. 61. 102522–102522.

Lagutina, Irina V., et al.. (2025). Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer. Cancer Research Communications. 5(10). 1796–1808.

Hagemann, Andrea R., Ian S. Hagemann, David G. Mutch, et al.. (2025). Enhancing Progestin Therapy with a Glucagon-Like Peptide 1 Agonist for the Conservative Management of Endometrial Cancer. Cancers. 17(4). 598–598. 4 indexed citations

Feng, Yue, Huining Kang, Kimberly K. Leslie, et al.. (2024). Early menopause and hormone therapy as determinants for lung health outcomes: a secondary analysis using the PLCO trial. Thorax. 79(10). 961–969. 2 indexed citations

Thiel, Kristina W., Eric J. Devor, Virginia L. Filiaci, et al.. (2022). TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. Journal of Clinical Oncology. 40(28). 3289–3300. 45 indexed citations

Bi, Jianling, Yuping Zhang, Eric J. Devor, et al.. (2021). Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy. Pharmaceuticals. 14(7). 682–682. 10 indexed citations

Santillan, Mark K., Richard C. Becker, David A. Calhoun, et al.. (2021). Team Science: American Heart Association’s Hypertension Strategically Focused Research Network Experience. Hypertension. 77(6). 1857–1866. 1 indexed citations

Bi, Jianling, A.M. Newtson, Yuping Zhang, et al.. (2021). Successful Patient-Derived Organoid Culture of Gynecologic Cancers for Disease Modeling and Drug Sensitivity Testing. Cancers. 13(12). 2901–2901. 50 indexed citations

Bosquet, Jesús González, Eric J. Devor, Kristina W. Thiel, et al.. (2021). Bacterial, Archaea, and Viral Transcripts (BAVT) Expression in Gynecological Cancers and Correlation with Regulatory Regions of the Genome. Cancers. 13(5). 1109–1109. 11 indexed citations

10.

Pineda, Henry Reyes, et al.. (2019). Differential DNA methylation in high-grade serous ovarian cancer (HGSOC) is associated with tumor behavior. Scientific Reports. 9(1). 17996–17996. 27 indexed citations

11.

Bender, David, Michael W. Sill, Heather A. Lankes, et al.. (2015). A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. PMC. 14 indexed citations

12.

Zaino, Richard J., William E. Brady, Kimberly K. Leslie, et al.. (2014). Histologic Effects of Medroxyprogesterone Acetate on Endometrioid Endometrial Adenocarcinoma. International Journal of Gynecological Pathology. 33(6). 543–553. 31 indexed citations

13.

Kresowik, Jessica D., Eric J. Devor, Bradley J. Van Voorhis, & Kimberly K. Leslie. (2014). MicroRNA-31 is Significantly Elevated in Both Human Endometrium and Serum During the Window of Implantation: A Potential Biomarker for Optimum Receptivity1. Biology of Reproduction. 91(1). 17–17. 58 indexed citations

14.

Aghajanian, Carol, Michael W. Sill, Kathleen M. Darcy, et al.. (2011). Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study. Journal of Clinical Oncology. 29(16). 2259–2265. 214 indexed citations

15.

Albitar, Lina, et al.. (2010). EGFR isoforms and gene regulation in human endometrial cancer cells. Molecular Cancer. 9(1). 166–166. 44 indexed citations

16.

Watson, William J., et al.. (2007). Targeted treatment using monoclonal antibodies and tyrosine-kinase inhibitors in pregnancy. The Lancet Oncology. 8(8). 738–743. 30 indexed citations

17.

Lange, Carol A. & Kimberly K. Leslie. (2005). Cáncer de mama y embarazo. 32(4). 547–558.

18.

Dai, Donghai, Elizabeth S. Litman, Eric Schonteich, & Kimberly K. Leslie. (2003). Progesterone regulation of activating protein-1 transcriptional activity: a possible mechanism of progesterone inhibition of endometrial cancer cell growth. The Journal of Steroid Biochemistry and Molecular Biology. 87(2-3). 123–131. 52 indexed citations

19.

Leslie, Kimberly K.. (2000). Estrogens in intrahepatic cholestasis of pregnancy. Obstetrics and Gynecology. 95(3). 372–376. 33 indexed citations

20.

White, Margueritte M., Stacy Zamudio, Troy Stevens, et al.. (1995). Estrogen, Progesterone, and Vascular Reactivity: Potential Cellular Mechanisms*. Endocrine Reviews. 16(6). 739–751. 128 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact